1. Home
  2. NVT vs UTHR Comparison

NVT vs UTHR Comparison

Compare NVT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nVent Electric plc

NVT

nVent Electric plc

HOLD

Current Price

$107.14

Market Cap

18.1B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$479.25

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVT
UTHR
Founded
1903
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
NVT
UTHR
Price
$107.14
$479.25
Analyst Decision
Strong Buy
Buy
Analyst Count
12
12
Target Price
$107.58
$495.08
AVG Volume (30 Days)
2.2M
407.3K
Earning Date
10-31-2025
10-29-2025
Dividend Yield
0.74%
N/A
EPS Growth
6.36
16.08
EPS
3.64
26.38
Revenue
$3,578,600,000.00
$3,128,400,000.00
Revenue This Year
$28.70
$13.64
Revenue Next Year
$14.60
$5.78
P/E Ratio
$29.53
$18.26
Revenue Growth
21.54
13.50
52 Week Low
$41.71
$266.98
52 Week High
$117.52
$492.62

Technical Indicators

Market Signals
Indicator
NVT
UTHR
Relative Strength Index (RSI) 54.10 56.13
Support Level $102.25 $474.59
Resistance Level $109.60 $489.99
Average True Range (ATR) 3.59 10.40
MACD 0.04 -1.66
Stochastic Oscillator 74.28 38.57

Price Performance

Historical Comparison
NVT
UTHR

About NVT nVent Electric plc

NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: